
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. has experienced robust growth in its point-of-care (POC) and formulary offerings, achieving over 100% growth during the recent buying season, which reflects strong demand for its services among medical professionals. The company's stock has risen 3.2% since September 8, indicative of positive market sentiment following a recent Memorandum, and suggests a favorable outlook for future performance. Additionally, the second-quarter guidance appears attainable, with the potential for upside, supported by increased visibility and upfront buying from expanded service offerings.
Bears say
Doximity is facing a challenging outlook due to revisions in downward guidance from its pharmaceutical clients, attributed to the prevailing economic uncertainty, which impacts the company's growth prospects for FY'23 and FY'24. Additionally, Doximity's shares are expensive compared to its software peers, which could lead to increased volatility if the company's performance fails to meet lofty investor expectations. The heightened scrutiny on financial results suggests that any failure to provide positive guidance could lead to significant market disappointment.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares